Methimazole NDC 71335-2218

NDC codes

FDA NDC Directory

Product NDC (as listed)71335-2218Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71335-2218Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
71335-2218-1	71335221801	30 TABLET in 1 BOTTLE (71335-2218-1)Marketed from Aug 31, 2023
71335-2218-2	71335221802	15 TABLET in 1 BOTTLE (71335-2218-2)Marketed from Aug 31, 2023
71335-2218-3	71335221803	90 TABLET in 1 BOTTLE (71335-2218-3)Marketed from Aug 31, 2023

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Methimazole
Generic name (nonproprietary): methimazole
Active ingredients: Methimazole — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202068
Marketing start: Apr 22, 2021
Listing expires: Dec 31, 2026
Other FDA classes: Thyroid Hormone Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 71335-2218_350884ec-5351-1828-e063-6294a90a2c10SPL ID 350884ec-5351-1828-e063-6294a90a2c10SPL set ID f74a8e69-79a1-4061-b42f-447e0780c04fRxCUI 197941UNII 554Z48XN5E
Pharmacologic class: Thyroid Hormone Synthesis Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471335221801 followed by a unit qualifier and the quantity

Package 71335-2218-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 13, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Methimazole tablets are indicated: In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option. To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 202068

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202068
Product	Strength	Form · route	Labeler	Product NDC
Methimazole	Methimazole 5 mg/1	TabletOral	Preferred Pharmaceuticals Inc.	68788-8883
Methimazole	Methimazole 10 mg/1	TabletOral	Preferred Pharmaceuticals Inc.	68788-4063
Methimazole	Methimazole 10 mg/1	TabletOral	Rising Pharma Holdings, Inc.	64980-265
Methimazole	Methimazole 5 mg/1	TabletOral	Rising Pharma Holdings, Inc.	64980-264